Luo Sa, Pauluhn Jürgen, Trübel Hubert, Wang Chen
Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100069, China; Department of Toxicology, Bayer Pharma AG, 42096 Wuppertal, Germany.
Department of Toxicology, Bayer Pharma AG, 42096 Wuppertal, Germany.
Toxicol Lett. 2014 Aug 17;229(1):85-92. doi: 10.1016/j.toxlet.2014.06.011. Epub 2014 Jun 6.
Various therapeutic regimes have been proposed with limited success for treatment of phosgene-induced acute lung injury (P-ALI). Corticoids were shown to be efficacious against chlorine-induced lung injury but there is still controversy whether this applies also to P-ALI. This study investigates whether different regimen of curatively administered budesonide (BUD, 10 mg/kg bw, i.p. bid; 100 mg/m(3)×30 min, nose-only inhalation), mometasone (MOM, 3 mg/kg bw, i.p. bid) and dexamethasone (DEX, 10, 30 mg/kg bw, i.p. bid), show efficacy to alleviate P-ALI. Efficacy of drugs was judged by nitric oxide (eNO) and carbon dioxide (eCO2) in exhaled air and whether these non-invasive biomarkers are suitable to assess the degree of airway injury (chlorine) relative to alveolar injury (phosgene). P-ALI related analyses included lung function (enhanced pause, Penh), morbidity, increased lung weights, and protein in bronchial alveolar lavage fluid (BALF) one day postexposure. One of the pathophysiological hallmarks of P-ALI was indicated by increased Penh lasting for approximately 20 h postexposure. Following the administration of BUD, this increase could be suppressed; however, without significant improvement in survival and lung edema (increased lung weights and BALF-protein). Collectively, protocols shown to be efficacious for chlorine (Chen et al., 2013) were ineffective and even increased adversity in the P-ALI model. This outcome warrants further study to seek for early biomarkers suitable to differentiate chlorine- and phosgene-induced acute lung injury at yet asymptomatic stage. The patterns of eNO and eCO2 observed following exposure to chlorine and phosgene may be suitable to guide the specialized clinical interventions required for each type of ALI.
针对光气诱导的急性肺损伤(P-ALI),人们提出了各种治疗方案,但治疗效果有限。皮质类固醇已被证明对氯诱导的肺损伤有效,但对于其是否也适用于P-ALI仍存在争议。本研究调查了不同剂量的布地奈德(BUD,10mg/kg体重,腹腔注射,每日两次;100mg/m³×30分钟,仅经鼻吸入)、莫米松(MOM,3mg/kg体重,腹腔注射,每日两次)和地塞米松(DEX,10、30mg/kg体重,腹腔注射,每日两次)治疗方案是否能有效缓解P-ALI。通过呼出气体中的一氧化氮(eNO)和二氧化碳(eCO2)来判断药物疗效,以及这些非侵入性生物标志物是否适合评估相对于肺泡损伤(光气)的气道损伤(氯)程度。P-ALI相关分析包括暴露后一天的肺功能(增强暂停,Penh)、发病率、肺重量增加以及支气管肺泡灌洗液(BALF)中的蛋白质含量。P-ALI的病理生理特征之一是暴露后Penh增加持续约20小时。给予BUD后,这种增加可以被抑制;然而,生存率和肺水肿(肺重量增加和BALF-蛋白质)没有显著改善。总体而言,已证明对氯有效的方案(Chen等人,2013年)在P-ALI模型中无效,甚至增加了不良影响。这一结果值得进一步研究,以寻找适合在无症状阶段区分氯和光气诱导的急性肺损伤的早期生物标志物。暴露于氯和光气后观察到的eNO和eCO2模式可能适合指导每种类型ALI所需的专门临床干预。